Chugai Pharma Manufacturing

Chugai Pharma Manufacturing is the primary production subsidiary of Chugai Pharmaceutical, a leading Japanese pharmaceutical company and a member of the Roche Group. The company is responsible for the global manufacturing of innovative medicines, specializing in both small molecule drugs and advanced biologics, including monoclonal and bispecific antibodies. It operates several state-of-the-art facilities across Japan, including the Utsunomiya, Fujieda, and Ukima plants, which adhere to international Good Manufacturing Practice (GMP) standards. Chugai Pharma Manufacturing plays a pivotal role in the supply chain for blockbuster therapies such as Hemlibra and Actemra, supporting patients worldwide. The company leverages Chugai's proprietary antibody engineering technologies to produce complex therapeutic proteins at scale. As a core member of the Roche global manufacturing network, it maintains high standards of quality and technical excellence in pharmaceutical production.